Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CXXC1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXXC1 Recombinant Protein (Wild-Type & CXXC Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for DNA-binding and methyltransferase complex assembly assays. |
View CXXC1 Products |
| Gene Delivery | CXXC1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target validation in hematopoietic lineages. |
View CXXC1 Products |
| Benchmark Ab | Anti-CXXC1 Recombinant Antibody High-affinity positive control for Western Blot, ChIP, and IP assays. |
View CXXC1 Products |
| Validator | CXXC1 siRNA Set Target-specific knockdown verification in cancer cell lines. |
View CXXC1 Products |
| Related Target A | SETD1A Core catalytic subunit of the histone methyltransferase complex recruited by CXXC1. Crucial for epigenetic co-targeting strategies. |
View SETD1A Products |
| Related Target B | MEN1 Scaffold protein in MLL/SET complexes. Synergistic target in MLL-rearranged leukemias. |
View MEN1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Unmethylated CpG DNA Binding Selectivity | Recombinant CXXC1 proteins strictly validated for correct folding and theoretical molecular weight, ensuring accurate DNA-protein interaction assays (EMSA/FP). |
| Off-Target Screening (Other CXXC-domain proteins) | Homolog panel proteins (e.g., KDM2A, DNMT1) available with high purity (>95%) for specificity counter-screening. |
| Lack of Controls | Sequence-verified benchmark antibodies and validated siRNA sets included for functional baseline establishment. |
| False Positives in Epigenetic Assays | Endotoxin-controlled, high-purity protein production to eliminate non-specific interference in cell-free screening. |
Live CXXC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CXXC1 therapeutics is intensifying, with major players shifting focus from traditional chromatin-modifying enzymes to specific epigenetic readers and scaffolding proteins. CXXC1 (also known as CFP1) plays a pivotal role in recruiting the SETD1A/B histone methyltransferase complexes to unmethylated CpG islands, making it a critical node in transcriptionally active chromatin states. As first-generation epigenetic therapies (such as HDAC or DNMT inhibitors) reach clinical limitations due to broad toxicity, the next wave of R&D is targeting highly specific reader domains like the CXXC zinc finger to selectively disrupt oncogenic transcriptional programs in leukemia and solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Epigenetics-focused Biotechs, Academic Consortia | MLL-Rearranged Leukemia, Colorectal Cancer | DNA-binding displacement assays (Requires high-purity CXXC1 CXXC domain protein) |
| PROTAC (Degrader) | Targeted Protein Degradation (TPD) Developers | Breast Cancer, Hematological Malignancies | Ubiquitination & ternary complex validation (Requires full-length CXXC1 and E3 ligase machinery) |
| Combination Therapies | Oncology-focused Pharma | Refractory Solid Tumors | Synergy screening (Requires stable cell lines generated via CXXC1 Lentivirus) |